Clinical trial NCT00447733: Integrated Treatment to Persons With Mental Disorders and Co-occurring Substance Use Disorders
Official title: Effects of Integrated Treatment to Persons With Mental Disorders and Co-occurring Substance Use Disorders
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Anxiety Disorders
Mood Disorders
Substance Use Disorders
Keywords: mental health
substance use
treatment
Lead sponsor: University of Oslo
Sponsor class: OTHER
Collaborators: name: SINTEF Health Research
First posted: 2007-03-15
Enrollment: 76
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine whether Integrated Treatment is effective in the treatment of anxiety and/or depression with co-occurring substance use disorders.

Detailed description: Patients with mental disorders and co-occuring substance use disorders are characterized by high suicide rates, high treatment drop-out rates and long-lasting interpersonal, work, school, health and legal problems. Because mental disorders and substance use disorders co-exist and interact, it may be important to provide a treatment that addresses the substance misuse and mental health problems in an integrated and comprehensive way. Additionally, the health services for patients with mental health and substance use disorders are usually provided by different services and health professionals that rarely cooperate or have qualifications on both kinds of disorders. This also calls for an integration of the services on an organizational level. This approach of integrating services and treatment approaches for both diseases in a comprehensive way is called Integrated Treatment. Several studies have shown that Integrated Treatment is effective in treating the comorbidity of severe mental illness and substance use disorders. The over-all aim of this study is to evaluate the effects of evidence-based Integrated Treatment in anxiety and/or depression with co-occurring substance use disorders. The effects of the treatment will be assesses on changes in substance use and psychopathology.

Comparison: patients receiving treatment-as-usual or non-manualized treatment at general mental health outpatients clinics.

Eligibility criteria: Inclusion Criteria:

* clinical diagnosis of substance use disorder
* clinical diagnosis of anxiety disorders
* clinical diagnosis of nonpsychotic mood disorders
* written consent
* planning to live in the catchment area during the treatment

Exclusion Criteria:

* schizophrenia spectrum disorders
* other psychotic disorders
* mental retardation
* nicotine abuse/dependency only
* prescription drug abuse/dependency only
* planning to move out of the catchment area during the study
* not able to read or write Norwegian

Primary outcomes:
measure: The Symptom Check List 90 (SCL90-r), The Alcohol Use Disorder Identification Test (AUDIT), The Drug Use Disorder Identification Test (DUDIT).
timeFrame: Change during 6 and 12 months follow-up
Secondary outcomes:
measure: The Addiction Severity Index (Europ ASI)
timeFrame: Change during 6 and 12 months follow up
Other outcomes:
Locations:
Study officials:
affiliation: Alcohol and Drug Treatment Health Trust in Central Norway; Norwegian Centre of Addiction Research, University of Oslo
name: Rolf W. Gråwe, Ph.D
role: PRINCIPAL_INVESTIGATOR
References:
citation: Wusthoff LE, Waal H, Grawe RW. The effectiveness of integrated treatment in patients with substance use disorders co-occurring with anxiety and/or depression--a group randomized trial. BMC Psychiatry. 2014 Mar 5;14:67. doi: 10.1186/1471-244X-14-67.
citation: Wusthoff LE, Waal H, Grawe RW. When research meets reality-lessons learned from a pragmatic multisite group-randomized clinical trial on psychosocial interventions in the psychiatric and addiction field. Subst Abuse. 2012;6:95-106. doi: 10.4137/SART.S9245. Epub 2012 Aug 16.